Tag Archives: Weight Management

Why You Can’t Find Wegovy, the Weight-Loss Drug

Novo Nordisk

NVO 0.61%

A/S flubbed the launch of its buzzy new weight-loss drug Wegovy, missing out on hundreds of millions of dollars in sales and squandering a head start before a rival could begin selling a competing product.

Wegovy is among a new class of drugs that health regulators have approved to cut the weight of people who are obese, a goal long sought by doctors and patients. Their weight-dropping potential became a viral sensation on social media. Elon Musk tweeted about Wegovy in October. And a related drug for diabetes, Ozempic, is a hot topic in Hollywood among celebrities seeking to stay thin, according to doctors.

SHARE YOUR THOUGHTS

Will Novo Nordisk A/S be able to retain its competitive edge with its weight-loss drug? Why or why not? Join the conversation below.

Yet Denmark-based Novo underestimated how big demand for the drug would be, and wasn’t ready to make enough to fill the prescriptions that flooded in after U.S. approval last year. Then a contract manufacturer halted production to address inspection issues.

“We should have forecasted better, which we did not,” Novo Chief Executive

Lars Fruergaard Jørgensen

said. “Had we forecasted that, we would have built a different supply chain.”

The missteps have proven costly for Novo, which was forced to ration Wegovy to patients who already had started taking it. The company has recorded around $700 million in sales to date, well short of the $2 billion in 2021 and 2022 sales that some analysts had projected before supply issues hit.

Novo Nordisk Chief Executive Lars Fruergaard Jørgensen admits the drug company misjudged how popular Wegovy would be.



Photo:

Carsten Snejbjerg/Bloomberg News

Amber Blaylock, a music teacher from Springfield, Mo., said she has been trying to get Wegovy to help her reduce weight since hearing about the drug on TikTok and YouTube. She asked her doctor in September to prescribe it, but hasn’t been able to find it. 

“Frustrated and impatient for sure,” said Ms. Blaylock, 29 years old.

To turn things around, Mr. Jørgensen said Novo has increased its capacity to make Wegovy and plans a “relaunch” early next year, which should fulfill all orders.

Novo, however, lost valuable time establishing a beachhead in the lucrative obesity-drug market before rival

Eli Lilly

LLY 1.20%

& Co. can enter. Lilly is expected to launch a similar, competing drug named Mounjaro late next year or in early 2024.

The market for anti-obesity drugs, now worth $2.4 billion worldwide, could reach $50 billion in 2030, Morgan Stanley estimates.

“Novo has left the door open for Lilly,” said BMO Capital Markets analyst Evan David Seigerman. 

Mr. Jørgensen said the company can regain lost ground because of high demand for Wegovy and the large potential for what is still a mostly untapped market. He said he was unconcerned with the looming competition with Lilly’s drug, because there is room for both products.

“We disappointed physicians and patients in the first round,” he said. “The company wants to be better prepared for the second round.” Novo lists Wegovy at $1,349 a month. Some commercial insurers cover the drug.  

Wegovy works by imitating a hormone called GLP-1, which occurs naturally in the body and suppresses appetite, among other effects. 

Novo developed GLP-1 drugs to treat diabetes. In 2017, the company began selling semaglutide, the active ingredient in Wegovy, under the brand name Ozempic to treat diabetes. 

During the drug’s development, Novo found that weight loss was a side effect, prompting the company to probe using semaglutide to treat obesity. A key trial found that Wegovy helped people with a high body-mass index shed up to 15% of their weight, surpassing the results for older obesity drugs like Novo’s Saxenda. 

Saxenda and other older weight-loss drugs had sold modestly, partly due to their limited weight loss, as well as some unpleasant side effects and the refusal of many health insurers to pay up. 

Novo worked with Catalent to fill its Wegovy weight-loss drug into syringes.



Photo:

yara nardi/Reuters

Given the experience, Novo figured Wegovy sales would increase gradually. To augment its own production, Novo contracted with a single manufacturer,

Catalent Inc.,

to fill the drug into syringes. Novo said it thought it would have time to add manufacturing capacity to meet a gradual increase in demand.

Wegovy may be superior to older drugs, but “we thought it would still be a journey to open up the market,” Mr. Jørgensen said. 

When Novo started selling Wegovy in the U.S. in June last year, however, demand took off. Doctors with large followings on social media touted Wegovy as groundbreaking, while users posted photos holding injection pens and shared their progress losing weight. 

“Demand for these new agents has been unlike anything I’ve ever seen in my time in medicine,” said Dr. Michael Albert, a physician specializing in weight-loss treatment at telehealth provider Accomplish Health who has consulted for Novo. Many of his patients began asking about Wegovy, he said, after they heard about it in Facebook groups or on TikTok.

It took only five weeks for doctors to write new prescriptions for Wegovy at the same weekly volume that Saxenda took four years to reach, according to Mr. Jørgensen. “It’s a completely different ballgame that we’re in,” said Ambre Brown Morley, the company’s vice president of media and digital global communication. 

Within weeks, supplies were strained. Novo warned that patients might experience delays in receiving their prescriptions. Then in December 2021, Catalent temporarily stopped deliveries and manufacturing at its plant after Food and Drug Administration inspections found faulty air filters and damaged equipment.

To date, Novo has recorded around $700 million in Wegovy sales compared with the $2 billion in 2021 and 2022 sales that some analysts had projected before supply issues emerged.



Photo:

JACOB GRONHOLT-PEDERSEN/REUTERS

Many people who couldn’t get Wegovy for weight loss have sought prescriptions for Novo’s Ozempic and Lilly’s Mounjaro, according to analysts, even though the FDA hasn’t approved the latter two drugs for such use. Ozempic sales increased so much that certain doses are in short supply through at least January, the FDA said.

Lilly is studying Mounjaro, its GLP-1-containing drug for diabetes, for weight loss. 

Novo and Lilly said they don’t promote their diabetes drugs for the “off-label” use treating obesity.

A Catalent spokesman said the company is still making improvements to the plant and working with customers to limit the impact of supply constraints on patients. The company restarted filling Wegovy syringes at the facility in the spring. 

Novo has been amassing a sufficient inventory before the Wegovy relaunch, Mr. Jørgensen said. When Wegovy relaunches, he said, insurance coverage will be broader than when the drug first went on sale. 

Write to Peter Loftus at Peter.Loftus@wsj.com and Denise Roland at denise.roland@wsj.com

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Read original article here

No ‘good’ vs. ‘bad’ foods: 10 eating ‘patterns’ to prevent heart disease, death

Looks like we’ve been talking about healthy eating all wrong. 

The American Heart Association released a new scientific statement on Tuesday that encourages everyone to focus on their overall dietary “patterns” to take care of their tickers, rather than zeroing in on foods, ingredients and drinks that are “good” or “bad” for their hearts.

The full “2021 Dietary Guidance to Improve Cardiovascular Health” was published in the Association’s flagship journal Circulation on Tuesday. And this more modern approach to nutrition is intended to adapt more easily to different cultural traditions, individual likes and dislikes, as well as societal issues such as whether most meals are made and eaten at home, or picked up on-the-go while people are at work or school.

“It does not need to be complicated, time consuming, expensive or unappealing.”

“We can all benefit from a heart-healthy dietary pattern regardless of stage of life, and it is possible to design one that is consistent with personal preferences, lifestyles and cultural customs,” said Alice H. Lichtenstein, the chair of the scientific statement writing group, in a statement.

“It does not need to be complicated, time consuming, expensive or unappealing,” added Lichtenstein, who is the director of the Cardiovascular Nutrition Team at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University in Boston. 

She concedes that adopting heart-healthy eating habits such as choosing the fish entrée over the steak at a restaurant, or opting for brown rice instead of fried white rice from your favorite Chinese takeout joint, may feel strange at first. “It might take a little planning, however, after the first few times it can become routine,” she said.

Here’s the American Heart Association’s 10 steps for a dietary pattern to promote heart health:

  1. Balance food and calorie intake with physical activity to maintain a healthy weight.
  2. Choose a wide variety of fruits and vegetables, and eat plenty of produce, to get a full range of nutrients from food — rather than from supplements.
  3. Choose whole grains and other foods made up mostly of whole grains, such as whole wheat, oatmeal, brown rice and popcorn.
  4. Include healthy sources of lean and/or high-fiber protein such as plant proteins (nuts and legumes); fish or seafood; low fat or non-fat dairy; lean cuts of meat — and limit red and processed meats.
  5. Use liquid non-tropical plant oils such as olive or sunflower oils.
  6. Choose minimally-processed foods (such as a bag of salad or  roasted, unsalted nuts) rather than ultra-processed foods (such as sugary cereal, potato chips or smoked sausage) as much as possible.
  7. Minimize eating and drinking food and beverages with added sugars.
  8. Choose or prepare foods with little or no salt.
  9. Limit alcohol consumption. And if you don’t drink, do not start. 
  10. Apply this guidance no matter where food is prepared or consumed, such as whether you’re at home, dining out or ordering takeout.

These tips should sound familiar; much of this advice has been supported by scientific research for years. 

Read more: These 4 diet and lifestyle changes can lower your cancer risk by almost 20%

And that’s the point. The AHA’s new statement reflects the latest scientific evidence on the benefits of heart-healthy eating throughout life, and how poor diet quality is strongly associated with an increased risk of cardiovascular disease and death.

Weight Watchers took a similar step a few years ago. The company was founded to help people lose weight, and watching the scale was literally in its name. But in 2018, Weight Watchers International Inc. announced it was shifting its focus from weight loss to a wellness journey, and it changed its legal name to WW International Inc
WW,
-1.19%.
in September 2019. More people were joining Weight Watchers for “something more than getting into a size 8,” Chief Executive Mindy Grossman said in 2018. “Today, healthy is the new skinny.” And the brand has been customizing its lifestyle guides for individual users, and moving away from the old school “one size fits all” approach.

Related: ‘The Covid 15?’ If only — this is how much weight the average person actually gained during the pandemic

And now for the first time, the AHA is highlighting challenges such as societal factors that can make it tougher for people to learn or maintain healthy eating patterns. For example, about 2.3 million Americans live in food deserts more than one mile away from a supermarket and do not own a car, according to federal data, making it difficult to shop for more nutritious and less processed foods. The COVID-19 pandemic also saw more people ordering takeout from home — and, conversely, dining out spiked as bars and restaurants have reopened in some areas.

The AHA highlighted the following societal challenges that can make it harder to start or maintain a heart-healthy eating pattern:  

  • Widespread dietary misinformation from the internet.
  • A lack of nutrition education in grade schools and medical schools.
  • Food and nutrition insecurity — according to references cited in the statement, an estimated 37 million Americans had limited or unstable access to safe and nutritious foods in 2020.
  • Structural racism and neighborhood segregation, whereby many communities with a higher proportion of racial and ethnic diversity have few grocery stores but many fast-food outlets.
  • Targeted marketing of unhealthy foods and beverages to people from diverse racial and ethnic backgrounds through tailored advertising efforts and sponsorship of events and organizations in those communities.

The guidance recommends public health action and policy changes to address these barriers, calling it “a public imperative.” 

The AHA statement also notes that this heart-healthy eating pattern is good for the environment. Popular animal products, particularly red meat (beef, lamb, pork, veal, venison or goat), have the largest environmental impact in terms of water and land usage, and contribute significantly to greenhouse gas emissions, compared with plant-based foods. “It is important to recognize that the guidance is consistent not only with heart health but also sustainability — it is a win-win for individuals and our environment,” said Lichtenstein.

Read original article here